CURRICULUM VITAE: Bernard Mark SMITHERS

ACADEMIC ADDRESS: Department of Surgery, University of Queensland, Princess Alexandra Hospital, Ipswich Rd., Brisbane, Australia 4102

PRIVATE PRACTICE: GIAST Clinic, Suites 30,31 Mater Medical Centre, 293 Vulture St., South Brisbane, Australia 4101

E MAIL: M.Smithers@uq.edu.au

PLACE OF BIRTH: Brisbane, Queensland.

EDUCATION: TERTIARY: University of Queensland 1972-1977 M.B.B.S.

POSTGRADUATE: Fellow Royal Australasian College of Surgeons, Feb 1985 Fellow Royal College of Surgeons of England, Jan 1986

QUALIFICATIONS: M.B.B.S.(Qld), F.R.A.C.S., F.R.C.S.(Eng).

PRESENT APPOINTMENTS:ACADEMIC: Associate Professor of Surgery, University of Queensland (Part Time) Level D, Academic (Point 0404) Honorary Associate, NH&MRC Trials Centre, Faculty of Medicine, University of Sydney

CLINICAL: Senior Visiting Medical Officer - Trauma/General Surgeon, Director, Upper GI and Soft Tissue Unit, Princess Alexandra Hospital.

PREVIOUS APPOINTMENTS:Consultant Surgeon Appointments.

• Locum Surgeon, Flying Surgeon Service, Longreach, Australia, Jan 1987.• Locum Vascular Surgeon, Princess Alexandra Hospital, Jan-Feb 1988.• Visiting Consultant Surgeon, Logan Hospital, June 1990-91.• Clinical Lecturer, University of Queensland, Department of Surgery, Princess Alexandra

Hospital, Brisbane. Sept 1987 - June 1988.• Senior Lecturer in Surgery, University of Queensland, Department of Surgery,

Trauma/General Surgeon, Princess Alexandra Hospital, Brisbane. June 1988 - April 1995.

• Associate Professor in Surgery, University of Queensland, Department of Surgery, Princess Alexandra Hospital, Brisbane. May 1995 -

• Visiting Surgeon, Upper GI and Soft Tissue, Unit Princess Alexandra Hospital, Brisbane. May 1995 - July 1996

• Senior Visiting Surgeon, Director, Upper GI and Soft Tissue Unit, Princess Alexandra Hospital, Brisbane. July 1996 – present time

LICENSURE: Medical Board of Queensland. General Medical Council of England.

SPECIALTY CERTIFICATION: General Surgery

PROCEDURAL CERTIFICATION: Colonoscopy, Gastroscopy

PROFESSIONAL MEMBERSHIPS:1978 Medical Defence Society of Queensland 1978-1997

1980 Australian Sports Medicine Federation 1980-2006) 1982 Visa Qualifying Examination of Educational Commission for Foreign

Medical Graduates (E.C.F.M.G.)1985 Royal Australasian College of Surgeons (Current)

1986 Royal College of Surgeons of England (Current)1986 World Association of Hepato Pancreatico-Biliary Surgeons1988 Gastroenterological Society of Queensland (Current)1991 Clinical Oncological Society of Australia (Current)1992 Gastroenterological Society of Australia (1992 – 2008)1992 Surgical Research Society of Australasia (Current)1994 Eastern Co-operative Oncology Group (E.C.O.G.) - Investigator (Current)1997 United Medical Protection Society (1997 - 2007)1998 International Association of Hepato-pancreaticobiliary Surgeons(Current)1999 International Society of Diseases of the Esophagus(Current)2000 Society of Surgical Oncology (USA)- (Current)2007 Australia and New Zealand Gastro-Oesophageal Surgeons Association

(Current)2007 Avant Medical Insurance (Current)

AWARDS:1992: Queensland Cancer Fund - E.S.A. International Scholarship

Study and Travel Programme:MD Anderson Cancer Centre - Houston, Texas, Department of Surgery, University of Kentucky, Louisville, KentuckyMemorial Sloan Kettering Cancer Institute, New York.Prince of Wales Hospital, Chinese University, Hong Kong.

2003: Philip Goatcher Surgeon in Residence – Royal Perth Hospital. July, Perth 2007: Nimmo Visitor – Royal Adelaide Hospital October 29 – November 1, Adelaide, Australia. 2008: Distinguised Invited Visitor - Combined Royal Australasian College of Surgeons and College of Surgeons of Hong Kong Annual Scientific Congress. May 13 – 18, Hong Kong

CLINICAL INTERESTS:UPPER G.I. SURGERY - I am one of four Surgeons and the Chairman/ Director of the Upper G.I./Soft Tissue Unit at Princess Alexandra Hospital. My interests and research include: (i)Malignant diseases of the oesophagus and stomach. In 1994 we established a multi-disciplinary Upper GI Oncology Clinic, involving surgery, medical oncology and radiation oncology. We presently run a weekly multidisciplinary meeting to discuss all new and problem cases of cancer of Gastric and Oesophageal Malignancy. All oesophageal and gastric malignancies are documented onto a prospective database. We see over 100 new patients with malignant dysphagia each year and operate on 45%. (ii) Benign conditions notably Gastro-oesophageal Reflux. In collaboration with my colleagues Professor David Gotley and Les Nathanson we are documenting all patients who have had surgery.(iii) We are a tertiary referral centre for complicated upper GI problems including patients with Achalasia and those who have had previous surgery with functional problems.

MELANOMA - I am the Senior Surgeon in the Melanoma Clinic at Princess Alexandra Hospital. This is a multi-disciplinary clinic with medical oncology and radiotherapy, and is the base for the initiation of a number of clinically based research projects and trials. I am Chairman of The Queensland Melanoma Project which is the research arm of the Melanoma Clinic. This group runs and co-ordinates the clinically based trials for patients managed through the Melanoma Clinic.

ENDOSCOPY - DIAGNOSTIC - I am accredited in colonoscopy and gastroscopy with the combined committee of the G.E. Society of Australia and the Royal Australasian College of Surgeons.

ENDOSCOPIC SURGERY - I am experienced in advanced Laparoscopic Surgery including cholecystectomy, Nissen fundoplication, oesophageal resection, adrenalectomy and splenectomy. At the time of the introduction of laparoscopic surgery, I had been on the teaching faculty for practical courses, as well as attending many workshops.I have coordinated a prospective randomised trial of open versus laparoscopic appendicectomy.

TRAUMA - The Princess Alexandra Hospital is a major metropolitan hospital dealing with primary, secondary and tertiary referrals of patients with major trauma. I am interested in the assessment, care and documentation of these patients. In the past I had the responsibility to organize the trauma roster and service with my earlier appointment to the hospital including the title of Trauma surgeon.

I have been a Director and Instructor of the Early Management of Severe Trauma Course which is run by the Australasian College of Surgeons. I have taught on a number of courses in Australasia and more recently have directed a number of participant and instructor courses. From January 1995 to February 2000 I was on the national EMST Committee.

RESEARCH

OESPHAGUS – Active

NH&MRC:APP 1011782 – Docetaxel with or without radiation therapy for resectable oesophageal adenocarcinoma based on early PET response to induction chemotherapy. (DOCTOR trial)CIA Andrew Barbour; CIB Bernard Smithers, CIC Bryan Burmeister, CID Euan Walpole, CIE John Zalcberg, CIF Nigel Spry, CIG Garett Smith2011 – 13: $791,991.44

“Prospective assessment of Quality of Life after Intervention for oesophageal cancer”.Chief Investigators: Assoc. Prof. M Smithers, Professor D GotleySupport: Mater Private Hospital

Prospective documentation of Oesophageal and Gastric cancers managed within Princess Alexandra Hospital and the Mater Medical Centre.

OESPHAGUS – COMPLETEDNIHMolecular epidemiology of Barrett’s oesophagus and cancer.Chief Investigator: David WhitemanAssociate Investigators: G. Jameison, A Green, D Purdie, D Gotley, BM Smithers, D. WatsonSupport: National Institute of Health, USA - $US 1,250,000 2003 – 08.NHMRCTowards Prognostic Markers for Oesophageal Cancer Chief Investigator: David Whiteman Associate Investigators: Assoc Prof BM Smithers, Prof DC Gotley, Prof A Green Support: NH&MRC: 2006-8

Randomized trial of Surgery alone compared with chemoradiation prior to surgery for operative oesophageal carcinoma. This was a National multicentred trial co-ordinated by a management committee under the auspices of the Australasian Gastro Intestinal Trials Group and the Trans-Tasman Radiation Oncology Group. Chief Investigator: Assoc. Prof. B BurmeisterPrinciple Investigators: Assoc. Prof. M Smithers, Prof. J Denham, Dr S AcklandSupport: NHMRC 1996-1998 - $73,000 per annum

Epidemiology of Oesophageal Cancer. Chief Investigator: David WhitemanAssociate Investigators: Prof Adele Green, Assoc Prof M Smithers, Prof. David GotleySupport: Queensland Cancer Fund - $60,000 per annum 2001- 2002NH&MRC programme grant to Queensland Institute of Medical Research

Randomised Phase II trial of preoperative chemotherapy compared with preoperative chemoradiation for operable carcinoma of the oesophagusInvestigators: Assoc Professor B. Burmeister, Assoc Professor M. Smithers, Prof D. Gotley, J. Harvey, E. Walpole, D. Thomson.Support: Internal

GASTRIC CANCER - ActiveCancer AustraliaRandomised phase III study of preop-chemoradiotherapy vs preop-chemotherapy for resectable gastric cancer.Support: Cancer Australia 570996 (app ID) $596625, 2009-2011Chief Investigator: Trevor Leong, Associate Investigators: Val Gebski, Mark Smithers, David Watson, Nigel Spry, John Zalcberg, Michael Michael, Alex Boussioutas

GIST – CompletedIntermediate and high risk localized, completely resected, gastro-intestinal stromal tumours (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery. Intergroup study (EORTC 62024). – 5% Australian sponsor; Australasian Gastrointestinal Trials Group (AGITG) Trial Management Committee: Dusan Kotachek, BM Smithers, B. Mann, G Van Hazel, Garret Smith, D Porter, D Watson, S Pieterse, J Simes, J Zalcberg, D Miller, M Hall 2005 - $90002, 2006 - $87002, 2007 - $76168

ENDOSCOPIC SURGERY - Active• “Pre and post-operative assessment for laparoscopic fundoplication”.

This study utilizes oesophageal physiology studies and quality of life instruments to objectively assess the results of all patients who have anti-reflux surgery, both in the short and long term.

• Prospective documentation of advanced laparoscopic surgery – cardiomyotomy, splenectomy, adrenalectomy

MELANOMA - ActiveNH&MRC: APP 1004999: Effects of nevogenesis susceptibility genes and phenotype correlation with dermoscopic characteristics of nevi. CIA Peter Soyer, CIB Richard Sturm, CIC David Duffy, CID Bernard Smithers.2011 -13, $535,206

Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III MulticenterRandomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in CutaneousMelanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node.Multicentre trial co-ordinated by John Wayne Cancer centre. PI Donald MortonLocal Investigators: BM Smithers, Gerard Bayley, Andrew Barbour

A phase 2 study of intralesional PV-10 in the treatment of metastatic melanoma.Sponsor – Provectus Pharmaceuticals, Delpharm ConsultantsChief Investigator (Qld) – BM Smithers Co-investigators – A Barbour, G. Bayley

A phase I study of Genvax for Stage IV metastatic Melanoma.Sponsor – Chief Investigator – BM SmithersCo-investigators – A Barbour, G Bayley, D. Thomson

DERMA Study - A phase III study of MAGE for patients with stage III metastatic melanoma. Sponsor – GlaxoSmithKline BiologicalsChief Investigator (Qld) – BM SmithersCo –investigators – A Barbour, G Bayley, D Thomson

MELANOMA RESEARCH - COMPLETEDNH&MRC Treatment of recurrent malignant melanoma by limb infusion of cytotoxic drugs and other techniques. Chief Investigator: Prof M RobertsPrinciple Investigators: A/Prof BM Smithers, A/Prof J Thompson and A/Prof C AndersonSupport NHMRC #981314: 1998 – 2000 $273,453

Preclinical development of a melanoma – selective drug:Chief Investigator: Dr P ParsonsPrinciple Investigator: Assoc. Prof M SmithersSupport: NHMRC 1998 – 2000 - $60,000 per annum

The role of TAPP and MHC Class ! expression in the response to melanoma immunotherapy using dendritic cells.Chief Investigator: Assoc Prof R ThomasPrinciple Investigators: Dr. Jabbar, Assoc Prof BM Smithers, E WalpoleSupport NH&MRC # 102515: 2000 – 2002 $104,000 per annum

Clinical trial of Autologous Melanoma Vaccine in Patients with Stage IV melanomaChief Investigator: Dr R ThomasAssociate Investigators: Assoc. Prof M Smithers, Dr E Walpole, Clinical Prof R McLeodSupport: Queensland Cancer Fund – 1999 – 2000 $40,000 per annum NH&MRC 2000 – 2002 $103,000 per annum

Phase III trial of an immunotherapy for stage III (AJCC) melanoma based on cultured autologous dendritic cells presenting autologous tumour cell analysis.Investigators: Prof Michael O’Rourke, A/Prof BM Smithers, Prof K. Ellem, C Schmidt, B O’Loughlin, D LincolnSupport: 2003-05 NH&MRC project grant to Queensland Institute of Medical Research 2006 – MS Principle Investigator - Queensland Cancer Fund (Grant Q57) – 2 years 71,700 per annum.

A trial of surgery versus surgery plus adjuvant radiotherapy in patients with resected nodal metastatic melanoma.Chief Investigator: M. Henderson, Peter MacCallum Cancer Centre, MelbourneAssociate Investigators: W. McCarthy, J. Thompson, B. Burmeister, BM Smithers Support: NH&MRC - $305000, 2003 – 06

"Physiological Pharmacokinetics in the Isolated Limb".Chief Investigators: M. Smithers / Prof. M. RobertsAssociate Investigator: Prof. W. Egerton Support: Queensland Cancer Fund 1993 - $60,000 University of Queensland - Cancer Research Fund 1994 - $31,400 Queensland Cancer Fund 1995-97 - $45,000 per annumPrincess Alexandra Hospital Foundation 1997 - $10,000Publications: 7 Posters: 4

Pharmacokinetics and pharmacodynamics of isolated limb perfusion and isolated limb infusion.Chief Investigator: Prof. M RobertsPrinciple Investigators: Assoc. Prof J Thompson, Assoc. Prof M Smithers, Dr C AndersonSupport: Princess Alexandra Hospital Foundation 1998 - $10,000

Development of Autologous Melanoma Vaccine for patients with stage IV metatastic melanoma.Chief Investigator: Dr R ThomasAssociate Investigators: Assoc. Prof M Smithers, Dr E Walpole, Clinical Prof R McLeodSupport: University of Queensland – Cancer Research Fund – 1998Queensland Cancer Fund – 1999 – 2000 $40,000 per annum

Phase III multicentred trial of wide excision alone versus wide excision and selective lymphadenopathy for malignant melanomaInvestigators: Assoc. Prof. M Smithers, Clinical Prof R McLeodThis trial is co-ordinated by the John Wayne Institute – California, USACommenced 1998. Accrual closed, follow up continues.Support: John Wayne Cancer Institute - $73,400 (to 2004)

A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, versus BCG plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma. (Multicentred trial)Principle Researcher: BM SmithersAssociate Researchers: S. Jones, B. Burmeister, G. Bayley Sponsor: CancerVax Corporation, Santa Monica, USA

A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, versus BCG plus a Placebo as a Post-Surgical Treatment for Stage IV Melanoma. (Multicentred trial)Principle Researcher: BM SmithersAssociate Researchers: E Walpole, G. BayleySponsor: CancerVax Corporation, Santa Monica, USA

A Phase II Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, in patients with in-transit metastatic melanoma. (Multicentred trial)Institutional Principle Researcher: BM SmithersAssociate Researchers: E Walpole, G. Bayley, S. Jones, A. BarbourSponsor: CancerVax Corporation, Santa Monica, USA

Phase I open label cohort study of two doses of Cavatak (coxsackievirus A21) given intratumorally in stage IV melanoma.Sponsor – Virolytics 2006-09Chief Investigator (Qld) – BM Smithers

OTHER:"Studies of the Abrogation of Islet Destruction by Immunointervention". 1987-1990.Chief Investigator: Dr. M. GreenAssociate Investigator: M. Smithers This project was supported by the Department of Surgery at Princess Alexandra Hospital.Publications: 1 Posters: 7

OTHER CLINICAL – completed :“Randomised study of laparoscopic appendectomy versus open appendectomy”. (Published)“Study of General Surgical aspects in Severe Pelvic Trauma”, managed at Princess Alexandra Hospital.“Peri-operative assessment audit of the first 100 patients having laparoscopic cholecystectomy”, at Princess Alexandra Hospital.

TEACHING: Undergraduate – Medical 1987 - 99Year 5 – Coordinator & Examiner of Medicine V Studies 1993 – 9 Surgical pathology tutorials 1 hour/week Small group tutorials 1 hours/week Large group seminars 2 hours/week Lectures – nine per year.Year 6 - Tutorials

Undergraduate – Physiotherapy Year 2 - Two Lectures

Graduate Medical Course: 2000 - present Year3 – Clinical Bedside Coaching and TutorialsYear 2: Lecture – “Malignant melanoma”

Postgraduate Surgical Trainee teaching sessions and clinical discussions. Tutorials on anatomy and surgical pathology. Lecture to Family Medicine Programme on abdominal pain and melanoma. 1990 - 99 AMC Candidates – Lecture on Trauma 2000 -2003Post-Graduate Student Supervision 1992: A. Grabs - Master Medical Science

ADMINISTRATIONPRESENTRoyal Australasian College of Surgeons Member, Queensland State Committee, RACS, 2006 – present Executive, Section of Academic Surgery

Australian and New Zealand Gastro-Oesophageal Surgeons Association (ANZGOSA). Vice President, 2006 – 2010 (President elect) President, 2010 -

Queensland Institute of Medical Research Member, Medical Advisory subcommittee 2001 – Present Princess Alexandra Hospital Director, Upper GI / Soft tissue Unit 1996 – Present Princess Alexandra Foundation, scientific advisory committee, 2006

Australasian Gastrointestinal Trials Group Member, Scientific advisory committee 1995 – present

Queensland Health Member, State Surgery Advisory Committee, 2008 – present Chair, Oesophago-gastric cancer collaborative, 2009 - present

Mater Private Hospital Member, Operating Theatre advisory committee 2002 – 2007 Chair, Operating Theatre advisory committee 2008 - present

Melanoma Patients Australia Medical Director

Melanoma Advisory Foundation Trustee

ADMINISTRATIVE - PAST

University of Queensland• Coordinator and Chief Examiner V year surgery 1993 – 1999

Royal Australiasian College of Surgeons • Organising Committee. R.A.C.S. Qld Branch, Annual Scientific Meeting, 1988. • Chairman, Organising Committee - Symposium on the Acute Abdomen, Sheraton Hotel, November 1990.

R.A.C.S. C.M.E. Activity. • RACS Supervisor of Surgical training, Princess Alexandra Hospital 1992 - 1996.• Executive, Organising Committee and Member of the Scientific Committee, Annual Scientific Congress

for RACS 1997. • National Committee, Early Management Severe Trauma course 1995-2000• Member, Regional Subcommittee of the Board in General Surgery 1992 – 1996• Chairman, Regional Subcommittee in General Surgery 1996 – 2002• Member, National Board of General Surgery 1996 – 2002 Scientific Convener, RACS Annual Scientific Congress, 2003 Convener, Section Surgical Oncology, RACS Annual Scientific Congress, 2003 Examiner Primary OSCE 1991 – 2008 Convener, Annual Scientific Congress, RACS, 2008 Executive, Section of Surgical Oncology, 2001 – 2010 Member, Court of examiners, General Surgery, 2002 – 2010

Princess Alexandra Hospital• Establishment of Surgical Services at Logan Hospital and then subsequent provision of part-time service.

June 1990-1991.• Representative to Post Graduate Medical Education Committee 1996

Queensland Health Chair, Southern Zone Surgical Network, 2006 – 2010

Holy Spirit Hospital• Ethics Committee, medical representative 1995 – 1999• Medical Advisory Committee 1997 – 99

Clinical Oncological Society Of Australia• Convenor Section of GI oncology, Annual Scientific Meeting, 1996

• Chairman, Surgical Oncology Group, 1997 – 2000• Member of National Council, 1997 – 2000

• Convenor, Section Surgical Oncology, Annual Scientific Meeting, 2000 Convenor, Sections Surgical Oncology and Melanoma, Annual Scientific Meeting, 2005

Gastroenterological Society of Queensland • Executive Committee, 1990 – 1999

Queensland Institute of Medical Research • Member of Governing Council 1997 – 2001 (Ministerial Appointment)

Queensland Clinical Oncology Group• Member of the interim executive committee, 2000 - 2003• Member of the Commissioning team, 2000 – 2003

Peplin Biotech Pty/Ltd• Medical Advisory Committee 2000 – 2006

Queensland Cancer Registry • Member, Advisory Committee, 2002 – 2008

BIBLIOGRAPHY

Hickey MT, Williams PF, Webb EG, Hoedl AF, Wurm MT, Douglas NC, Smithers BM, Green AC, Soyer HP. Naevus surveillance pilot study: evaluation of a protocol for phenotypic naevus characterization. Aust J Dermatol 2011; In Press

Baade PD, Green AC, Smithers BM, Aitken JF. Trends in melanoma incidence among children: possible influence of sun protection programs. Exp Rev Anticancer Ther 2011;11:661-664.

Zingg U, Smithers BM, Gotley DC, Smith G, Aly A, Clough A, Esterman AJ, Jamieson GG, Watson DI. Factors associated with post-operative pulmonary morbidity after oesophageal resection for cancer. Ann Surg Oncol 2010;18:1460-68

Hirst J, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A. Actual 5-Year Survivors following oesophagectomy and predictors of survival. Ann Surg Oncol 2011;18:1766-74

Burmeister BH, Thomas JM, Burmeister E, Walpole ET, Harvey JA, Thomson DB, Barbour AP , Gotley DC, Smithers BM. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus ? – a randomised phase II trial. Eur J Cancer 2011; 47:354-360

Barbour AP, Jones M, Brown I, Gotley DC, Martin I, Thomas J, Clouston A, Smithers BM. Risk stratification for early esophageal adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2010;17:2494-2502

Baade PD, Hernandez EH, Freedman DM, Smithers BM, Fritschi L. No role for melanoma treatment in the association between melanoma and amyotropic lateral sclerosis or Parkinson’s disease. Neuroepidemiology 2010;35:303-304

Smithers BM, Fahey PP, Corish T, Gotley DC, Falk GI, Smith GS, Kiroff GK, Clouston AD, Whiteman DC, for the Austalian Cancer Study. Symptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australia. Med J Aust 2010; 193:572-577

Smithers BM. Minimally Invasive Esophgaectomy. Expert Rev Gastroenterol Hepatol 2010;4:91-99

Thomson IG, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A. Thoracoscopic assisted esophagectomy for esophageal cancer: Analysis of patterns and prognosis factors for recurrence. Ann Surg 2010;252:281-291

Foote MC, Burmeister BH, Thomas J, Smithers BM. A novel treatment for metastatic melanoma with intralesional rose Bengal and radiotherapy: a case series. Melanoma Res 2010;20:48-51

Barbour AP, Thomas J, Suffolk J, Beller E, Smithers BM. Isolated limb infusion for malignant melanoma: Predictors of response and outcomes. Ann Surg Oncol 2009;16:3463-3472

Shenfine J, Barbour AP, Wong D, Thomas J, Martin I, Gotley DC, SmithersBM. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the oesophagus treated by surgery alone. Dis Esophagus 2009;22:668-675

Kelly SL, Peters P, Ogg MJ, Li A, Smithers BM. Successful management of an aortoesophageal fistula caused by a fish bone – a case report and literature review. J Cardiothoracic Surg 2009;4:21

Burmeister BH, Walpole ET, D’Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA, Smithers BM. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-flurouracil for esophageal cancer. Invest New Drugs 2009;27:275-279

Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, Clouston AD, Hayward NK & Whiteman DC. Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High- Density Single-Nucleotide Polymorphism Arrays. Cancer Res 2008;68:4163-4172

Baxi S, Burmeister BH, Harvey J, Smithers BM. Salvage definitive chemoradiotherapy for locally recurrent oesophageal cancer after primary surgery: Retrospective review. J Med Imaging Radiat Oncol 2008;52:1-5

Smith E, DeYoung NJ, PAvey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Rieszkewicz AR, Clouston AD, Gotley DC, Devitt PG, Jameison GG, Drewe PA. Similarity of abberant DNA methylation in Barrett’s oesophagus and oesophageal adenocarcinoma. Molecular Cancer 2008;7:75

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response. Ann Surg Oncol 2008;15:2894-2902

Foote MC, Burmeister B, Burmeister E, Bayley G, Smithers BM. Desmoplastic melanoma: The role of radiotherapy in improving local control. ANZ J Surg 2008;78:273-276.

Shenfine J, Barbour A, Martin I, Smithers BM, Gotley DC. Letters and Comments: Consideration of mesh-related complications. Ann R Coll Surg Engl 2008;90:175

Whiteman DC Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC for the Australia Cancer Study. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinoma of the oesophagus. Gut 2008;57:173-80

Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH. Positron emission tomography and pathological

reponse to neoadjuvant therapy in adenocarcinoma of the oesophagus. Dis Esophagus 2008;21:151-8.

Smithers BM, Gotley DC Response to letter re: Comparison of outcomes between open and minimally invasive esophagectomy. Ann Surg 2008;247:397-8

Mark B. Commentary: Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic immunological status in patients undergoing esophagectomy. World J Surg 2007; 31:2158-2159. (note – journal misprint of my name in published article)

Burmeister BH, Walpole E, Thomas J, Smithers BM. Two cases of oesophageal carcinoma following corrosive esophagitis successfully treated with chemoradiation therapy. Asia Pacific J Clin Oncol 2007;3:108-111

Smithers BM, Cullinan M, Thomas JM, Martin I, Barbour AP, Burmeister BH, Harvey J, Thomson DB, Walpole E, Gotley DC. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. Dis Esophagus 2007;20:471-77

Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007;245:232-240

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiation treatement and chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34.

Daly TA, Burmeister BH, Smithers BM, Doody J, Kane A. Radiotherapy for metastatic melanoma presenting in pregnancy. Aust Radiol 2006;50:598-603.

Burmeister B,H, Smithers BM, Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C, Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma – Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 2006;81:136-142

Coory M, Smithers M, Aitken J, Baade P, Ring I. Urban-rural differences in survival from cutaneous melanoma in Queensland. ANZ J Population Health 2006:30;71-74

Leibman S, Smithers BM, Gotley DC, Martin I, Thomas J. Minimally invasive esophagectomy: short and term outcomes. Surg. Endoscopy 2006:20;428-33.

Coory M, Baade P, Aitken J, Smithers BM, McLeod GR, Ring I. Trends for in-situ and invasive melanoma in Queensland, Australia, 1982 – 2002. Cancer Causes and Control 2006:17;21-27.

Smithers BM. Commentary: A novel approach to oesophageal resection. ANZ J Surg 2005;75: 1029.

Smith L, Moore T, Smithers M, Prins J, O’Moore-Sullivan T. Effect of alpha-glucosidase inhibition on dumping syndrome. Aust NZ J Surg. 2005:75;1124-1126.

Burmeister BH, Walpole ET, Burmeister EA, Thomas J, Thomson D, Harvey JA, Smithers BM, Gotley DC. Feasibility of chemoradiation therapy with protracted infusion of 5-fluro-uracil for esophageal cancer patients not suitable for cisplatin. Int J Clin Oncol 2005;10:256-261.

Smith KJ, O’Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Whiteman DC for Study of Diseases of Digestive Health. Interactions among smoking, obesity, symptoms of acid refulx in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:2481-2486.

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley

DC, Joseph D, Millar J, North J, Walpole E, Denham J. A randomised phase III study comparing surgery alone with chemoradiation therapy followed by surgery for resectable carcinoma of the oesophagus: an intergroup study of the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Lancet Oncol 2005:6:659-668.

Burmeister BH, SmithersBM. Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors reply. Lancet Oncol 2005;6:825-826.

Byrne JP, Smithers BM, Nathanson LK, Martin I, Ong HS, Gotley DC. Symptomatic and functional outcome after laparoscopic reoperation for failed antireflux surgery. Br J Surg 2005;92:996-1001.

Harvey JA, Bessell JR, Beller E, Thomas J, Gotley DC, Burmeister BH, Walpole ET, Thomson DB, Martin I, Doyle L, Burmeister E, Smithers BM. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus: 2004:17;260-65.

Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E, Thomson D, Smithers BM. Assessing the response of oesophageal carcinoma to neoadjuvant therapy using oesophagogastroscopy. Br J Surg 2004:91;199-204.

Stowasser M, Gordon RD, Gunaseker TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, following “non-selective” screening of hypertensives attending a recently established Hypertension Unit. J Hypertension 2003;21:2149-2157.

Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister BH, Lamb DS, Joseph D, Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Do relapse patterns alter following chemoradiation for carcinoma of the oesophagus? Clin Oncology 2003;15:98-108

Smithers M, O’Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabber I, Barker K, Grimmett K, Walpole E, Thomas R. Clinical response after intradermal immature

dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immumother 2003; 52: 41-52.

Matheson BJ, Burmeister BH, Smithers BM, Gotley D, Harvey JA, Doyle L. Second primary oesophageal cancer following radiation for breast cancer. Radiat Oncol 2002; 65: 159- 163.

Burmeister BH, Baumann KC, Smithers BM et al. Radiation therapy following nodal surgery for melanoma: An analysis of toxicity. ANZ J Surg. 2002; 72: pp344-8

Ong HS, Smithers BM. Epidemiology of gastric Cancer in Australia. Gastric Cancer 2002; 5: 118-121.

Bessell JR, Adair WD, Smithers BM, Martin I, Menzies B, Gotley DC. Early reoperation for acute dysphagia following laparoscopic fundoplication. Brit. J Surg. 2002; 89: 783 - 786.

Belt PJ, Smithers M, Elston T. The triad of bilateral retinoblastoma, dysplastic naevus syndrome and multiple cutaneous malignant melanomas: a case report and review of the literature.Melanoma Res 2002; 12: 179-82.

Burmeister BH, Harvey J, Smithers BM, Gotley DC. The localisation of small esophageal cancers for radiation planning using endoscopic contrast injection- A report on a series of eight cases. Dis Esophagus 2001;14:28-31.

Thomas R, Padmanabha J, Chambers M, McFadyen S, Walpole E, Nielssen G, Smithers BM. Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma. Melanoma Res 2001; 11: 167-173.

Thompson JK, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001; 79: 1-9.

Smithers BM, Gotley DC, Martin I, Bessell J, McEwan D, Doyle L. Thoracoscopic mobilisation of the esophagus: A six year experience. Surg Endosc 2001;15:176-182.

Roberts MS, Wu ZY, Siebert GA, Anissimo YG, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localised limb malignancy. Melanoma Res. 2001;11:3.

Wu ZY, Smithers BM, Anderson C, Roberts MS. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? Melanoma Res 2000;10:47-54.

Bessell JR, Finch R, Gotley DC, Smithers BM, Nathanson L, Menzies B. Chronic dysphagia following laparoscopic fundoplication. Brit. J. Surg. 2000;87:1341-1345

Burmeister BH, Dickie G, Smithers BM, Hodge R, Morton K. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch. Otolaryngol. Head Neck Surg. 2000; 126: 205-208.

Thomas R, Chambers M, Boytar R, Barker K, Cavanagh L, MacFadyen S, Smithers M, Jenkins M, Andersen J. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res.1999; 9:474-481

Martin I, O’Rourke N, Gotley D, Smithers M. Laparoscopy in the management of diaphragmatic rupture due to blunt trauma. Aust NZ J Surg. 1998; 68: 584-586

Burmeister BM, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the oesophagus: current status and future direction. MJA 1997; 167: 349-350

Roberts MS, Wu ZY, Rivory LP, Smithers BM, Egerton WS, Weiss M. Relative dispersion of intravascular transit times during isolated limb perfusion for recurrent melanoma. Br J Clinical Pharmacol 1997; 44: 347-351

Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharm and Exp Theurap 1997; 282: 1131-1138

Smithers BM, Devitt P, Jamieson GG, Bessel J, Gotley D, Gill PG, Neely M, Joseph DJ, Yeoh EK, Burmeister B, Denham JW. A combined modality approach to the management of oesophageal cancer. Eur. J. Surg. Oncol. 1997; 23: 219-223

Wu ZY, Smithers BM, Parsons P, Roberts MS. Effects of perfusion conditions on melphalan tissue distribution in isolated perfused rat hindlimb bearing a human melanoma xenograft. Brit. J. Cancer 1997; 75: 1160-1166.

Wu ZY, Smithers BM, Roberts MS. Melphalan dosing-regimens for management of recurrent melanoma by isolated limb perfusions: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Research 1997; 7: 252-264

Wu, ZY, Roberts, MS, Parsons PG, Smithers BM. Isolated limb perfusion with melphalan for human melanoma xenografts in the hind limb of nude rats: a surviving model. Melanoma Research 1997; 7: 19-26.

Gotley DC, Smithers BM, Menzies B, Branicki FJ, Rhodes M, Nathanson L. Laparoscopic Nissen Fundoplication and Post-operative Dysphagia - Can it be Predicted? Ann Acad Med Singapore 1996; 25: 646-649.

Gotley DC, Rhodes M, Smithers BM, Branicki F, Menzies B, Nathanson L. Laparoscopic Nissen's fundoplication - 200 consecutive cases. Gut 1996; 78: 487-491.

Hansen J, Smithers BM, Schache D, Wall D, Miller BJ, Menzies B. Prospective randomized trial of laparoscopic versus open appendicectomy for acute appendicitis. World J Surg 1996; 20: 17-21.

Smithers BM, Theile DE, Dickinson IC, Thomson DB, Axelsen RA. Malignant sacrococcygeal germ cell tumour in an adult. Aust & NZ J Surg 1996; 66: 185-189.

Kelly B, Raphael B, Smithers BM, Swanson C, Reid C, Thomson D, Walpole E, McLeod R. Psychological responses to malignant melanoma: an investigation of traumatic stress reaction in life-threatening illness. Gen Hosp Psychiatry 1995; 17: 126-134.

Selvey L, Hogan P, Frazer IH, Smithers BM, Robinson D. HIV testing before surgery (letter). Aust J Public Health 1995; 19: 107-108.

Wu, ZY, Thompson, MJ, Roberts, MS, Grabs, AJ, Smithers, BM, Addison, RS, Conell, GR. High performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated into perfusion. J Chromat B, 1995; 673: 267-279.

Burmeister B, Smithers BM, Bryant G, McLeod GR. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-371.

Clark J, Grabs AJ, Smithers BM, Roberts MS, Parsons P. Melphalan uptake hyperthermic synergism and drug resistance in a human cell model for the isolated limb perfusion of melanoma. Melanoma Research 1994; 4: 365-370.

Nicol DL, Smithers BM. Laparoscopic approach to the left kidney avoiding colonic mobilization. J. Urol. 1994; 152: 1967-1969.

Lange B, Harper J, Smithers BM. Percutaneous fluoroscopic gastrostomy. A safe option. Med J Aust 1994; 161: 308-310.

Nicol DL, Winkle DC, Nathanson LK, Smithers BM. Laparoscopic Nephrectomy for benign renal disease. Brit J Urology 1994; 73: 237-241.

Kastrissios H, Triggs ES, Sinclair F, Moran P, Smithers M. Plasma concentrations of bupivacaine after wound infiltration of an 0.5% solution after inguinal hemiorrhaphy: a preliminary study. Eur J Clin Pharmacol 1993; 44: 555-557.

Nathanson LK, Gotley D, Smithers BM, Branicki F. Video-thorascopic primary repair of early distal oesophageal perforation. Aust & NZ J Surg 1993; 63: 399-403.

Walker NI, Smith MM, Smithers BM. Ultrastructure of human Melanosis coli with reference to its pathogenesis. Pathology 1993; 25: 120-123.

Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma - Patterns of recurrence. World J Surg 1992; 16: 186-190.

Green MK, Smithers BM, Moran JE. A Comparison of Techniques for Isolation of Mouse Islets. Transplant Proc 1992; 24: 235-236.

Smithers BM, O'Loughlin B, Strong RW. Diagnosis of ruptured diaphragm following blunt trauma. Results from 85 cases. Aust NZ J Surg 1991; 61: 737-741.

Theile DE, Smithers BM, Windsor JC, Strong RW. Primary adenocarcinoma in a colonic "oesophageal segment". Aust NZ J Surg 1991; 61: 953-955.

Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic melanoma - A clinico-pathological review of 45 cases. Aust NZ J Surg 1990; 60: 967-972.

Reasbeck PG, Smithers BM, Blackley P. Construction and management of ileostomies and colostomies. Dig Dis 1989; 7: 265-280.

Ross WB, Tweedie J, Leong YP, Wyman A, Smithers BM. Intercostal blockade and pulmonary function after cholecystectomy. Surgery 1989; 105: 166-169.

Geroulakos G, Taylor W, Smithers BM, Wilkins JL. Multiple enteroliths in a chronically obstructed duodenal loop after Roux en Y Biliary Diversion. Surgery 1987; 102: 883-885.

Ross WB, Tweedie J, Leong YP, Wyman A, Smithers BM. Does intercostal blockade improve patient comfort after cholecystectomy. Brit J Surg 1987; 74: 63.

Smithers BM, Cooksey G, Foster M, Blamey R. The availability of organs for transplantation: A three-year study. BMJ 1986; 293: 923.

Smithers BM, Theile D, Cohen J, Evans E, Davis NC. Emergency right hemicolectomy in colon carcinoma: A prospective study. Aust NZ J Surg 1986; 56: 749-752.

Smithers BM, Welch C, Goodall P. Cystadenocarcinoma of the pancreas presenting in pregnancy. Brit J Surg 1986; 73:591.

Smithers BM, Myers PT. Injuries in sport: A prospective casualty study. Med J Aust 1985; 142:457-461.

Smithers BM, Wall D, Weedon D. Actinomycosis of the gall bladder. Aust NZ J Surg 1983; 587-588.

PUBLISHED ABSTRACTS(54)

Grob JJ, Santinami M, Trefzer U, Robert C, Smithers B, Mortier L, Levchenko E, Demidov L, Jouary T, Grange F, Testori A, Thompson J, Peeters O, Dreno B, Kirkman JM. Expression of

MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of screening tests for the DERMA trial. Pigment Cell Melanoma Res 2010;23:891

Agarwala S, Thompson J, Smithers BM, Ross MI, Coventry BJ, Minor DR, Scoggins C, Wachter EA. Chemoablation of metastatic melanoma with intralesional PV-10. Pigment Cell Melanoma Res 2010;23:883

Shafren DR, Hersey P, Smithers M. Phase I evaluation of intralesional administration of oncolytic Picovirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma. Pigment Cell Melanoma Res 2010;23:883

Smithers BM, Corish T, Moore S, Fahey P, Whiteman. Oesophageal cancer: outcomes from surgery in Australia 2003-05. Aust NZ J Surg 2010;80(suppl. 1):A96

Smithers BM, Burmeister B, Walpole E, Gotley D, Harvey J, Thomas J. Is radiation required in patients having preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomized phase II trial. Aust NZ J Surg 2010;80(suppl. 1):A96

Hirst J, Smithers M, Gotley D, Martin I, Thomas J, Barbour A. Minimally invasive oesophagectomy: health related-quality of life outcomes. Aust NZ J Surg 2010;80(suppl. 1):A96

Mackrill D, Kan YK, Stabler A, Smithers MB. Acute appendicitis, does the laparoscopic operation lead to more complications? Aust NZ J Surg 2010;80(suppl. 1):A33

Thomson IG, Waters B, O’Rourke P, Barbour A, Smithers M, Gotley D. Postoperative nomogram for disease specific survival after surgery for oesophageal cancer. ANZ J Surg 2009;79(suppl 1):A41

Hirst J, Smithers M, Gotley D, Martin I, Thomas J, Barbour A. Actual 5-year survival following oesophagectomy and predictors of survival. ANZ J Surg 2009;79(suppl 1):A41

Duong C, Smithers M, Thomas J, Gotley D, Martin I, Barbour A. Evolving management of high grade dysplasia in Barrett’s oesophagus. ANZ J Surg 2009;79(suppl 1):A42

Frankel AJ, Smithers BM, Thomas J, Barbour A, Bayley G. Morbidity of regional lymph node surgery for cutaneous melanoma. ANZ J Surg 2009;79(suppl 1):A80

Smithers BM , Doecke J, Corish T, Moore S, Whiteman D. Oesophageal Cancer: Patterns of Care in Australia. Asia Pacific J Clin Oncol 2008;4:Supp2, A30.

Whiteman D, SmithersBM, Gotley DC, Pandeya N, Sadeghi S, Green AC, Webb PM. The epidemiology of oesophageal cancer. Asia Pacific J Clin Oncol 2008;4:Supp2, A42.

Burmeister BH, Smithers BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D, Barbour A, Gotley D. A ranodomised phase II trial comparing pre-operative chemotherapy with

pre-operative chemoradiation therapy for localized carcinoma of the oesophagus. Asia Pacific J Clin Oncol 2008;4:Supp2, A47

Thompson JF, Hersey P, Smithers BM, Coventry B, Ross MI, Wachter E. Chemoablation of cutaneous and subcutaneous metastatic melanoma using PV-10. Asia Pacific J Clin Oncol 2008;4:Supp2, A72

Baumgartner L, Vivanti A, Smithers M. Jejunally fed patients post oesophagectomy / gastrectomy – are they getting all they need? – An audit at the Princess Alexandra Hospital. Asia Pacific J Clin Oncol 2008;4:Supp2,A107

Barbour A, Thompson I, Gotley DC, Jones M, Thomas J, Martin I, Smithers MB. Minimally invasive esophagectomy for esophageal cancer: analysis of recurrence patterns and prognostic factors of recurrence. Asia Pacific J Clin Oncol 2008;4:Supp2, A116

McFadyen, Herlaar H, Smithers M. Melanoma Patients Australia – A focus on patient support and advocacy. Asia Pacific J Clin Oncol 2008;4:Supp2, A147

Hughes A, Smithers BM, Thomas J, Martin I, Gotley DC, Barbour AP. Surgery for early adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2007;2 (supp): 103 (P237).

Barbour AP, Smithers BM, Gotley DC, Thomas J, Burmeister B, Thomson D. Refining oesophageal cacner staging after neoadjuvant therapy: Importance of primary tumour response.Aust NZ J Surg 2006:76(suppl. 1); A39.

Barbour AP, Smithers BM, Gotley DC, Thomas J, Burmeister B, Walpole E. Patterns and predictors of initial recurrence following resection for adenocarcinoma of the oesophagus and gastro-oesophageal junction. Aust NZ J Surg 2006:76 (suppl. 1); A40.

Barbour AP, Beller E, Smithers BM. Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of response and outcome. Ann Surg Oncol 2006; 13 (suppl):51

Burmeister BH, Smithers BM, Burmeister EA, Baumann KC, Davis SR, Krawitz H, Johnson C, Spry N. A prospective phase II study of postoperative radiation therapy following nodal surgery for malignant melanoma – trans tasman radiation oncology group (trog) study 96.06. Asia- Pacific J Clin Oncol 2005;1 (suppl.): A26.

Burmeister BH, Smithers BM. Preoperative adjuvant chemoradiation therapy for localized oesophageal cancer – study 9401 and the aftermath. Asia- Pacific J Clin Oncol 2005;1 (suppl.): A26. Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E, Thomson D, Smithers BM. Assessing the response of oesophageal carcinoma to neoadjuvant therapy using oesophagogastroscopy. Aust NZ J Surg 2003: 72 (suppl);A63.

Lim KH, Thomas J, Brown WA, Harvey J, Burmeister B, Walpole E, Thomson D, Martin I, Gotley DC, Smithers BM. A comparison of treatment outcome between adenocarcinoma and squamous cell carcinoma of the oesphagus. Aust NZ J Surg 2003: 72 (suppl);A63.

Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Smithers BM. The role of surgery in the management of locally advanced oesophageal carcinoma. Aust NZ J Surg 2003: 72 (suppl);A63.

BM Smithers, Burmeister BH, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph, J Millar, J North, E Walpole, D. Gotley. A randomized phase III trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes. Ann Surg Oncol 2003: 10(suppl);S10

BH Burmeister, BM Smithers, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph, J Millar, J North, E Walpole, JW Denham. A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized respectable cancer of the oesphagus. Proc ASCO 2002: 21;130a. abstract

J.R.Bessell, R.Finch, D.C.Gotley, B.M.Smithers, L.Nathanson, L.Doyle, B.Menzies. Chronic dysphagia following laparoscopic fundoplication. Brit J Surg 2000;87 (Suppl 1):32.

Smithers BM, Burmeister B, Baumann K. Phase II study assessing the role of radiotherapy after nodal surgery for metastatic melanoma. Aust NZ J Surg 2000:70(supp);A78

Gotley DC, Smithers BM, Martin I, Sanders G, Doyle LM. Barrett’s oesophagus: natural history and surveillance. Aust NZ J Surg 2000:70(supp);A89

Gotley DC, Smithers BM, Martin I, Bessell J, Doyle LM. Laparoscopic versus open surgery for oesophageal cancer. Aust NZ J Surg 2000:70(supp);A93

Smithers BM, Gotley DC, Doyle LM. Oesophageal cancer: Neoadjuvant therapy. Aust NZ J Surg 2000:70(supp);A93

Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L, Menzies B, Nathanson L. Elective laparoscopic fundoplication for reflux: 1000 consecutive cases with 1-5 year follow-up. J. Gastro Hepatol 1999: 14(supp); A144

Sanders G, Smithers BM, Gotley DC, Clouston A. High Grade Dysplasia in Barrett’s Oesophagus. J Gastro Hepatol 1999: 14(supp); A157

Bessell JR, Smithers BM, Gotley DC, Martin I, Harvey J, Burmeister B, Walpole E, Thomson D, Doyle L. The role of chemo-radiotherapy prescribed by a multi-disciplinary team for the palliative treatment of malignant dysphagia. J Gastro Hepatol 1999: 14(supp); A206

Ackland S, Burmeister BH, Smithers BM, Devitt P, Woods S, Gillies J, Walpole E, Findley M, Gray E, Denham J. Preoperative chemoradiation (CT/RT) versus surgery alone for resectable carcinoma of the oesophagus: An Australian randomised study. Proc. ASCO 1998, 17; 285a

Juffs HG, Thomson DB, Walpole ET, MacKintosh JF, Burmeister BH, Harvey JA, Smithers BM, Gotley DC. Retrospective Analysis of Concurrent Radiation and 5-Flurouracil (5FU) Alone for Oesophageal Cancer. Proc. ASCO 1998; 17: 293a .

Smithers BM, McLeod GRC, Anderson J, Strutton K. Establishing selective lymphadenectomy for cutaneous melanoma. Aust N.Z. J Surg. 1997; 67 (Supp): A33.

Smithers BM, Gotley DC, Smith C. Thoracoscopic oesophageal mobilisation for carcinoma. Aust N.Z. J Surg. 1997; 67 (Supp): A45.

Gotley DC, Smithers BM, Menzies B, Nathanson L. Successful application of laparoscopy to correction of gastro-oesophageal reflux. Aust N.Z. J Surg. 1997; 67 (Supp): A46.

Burmeister BH, Poulsen MG, Smithers BM, McLeod GR, Harvey JA, Morton K. Radiation therapy following nodal dissection for malignant melanoma: a report on a phase II study. Melanoma Res. 1997; 7 (Supp): S18.

Harvey JA, Burmeister BH, Smithers BM, McLeod GR. Metastatic malignant melanoma to the orbit: a report of nine cases. Melanoma Res. 1997; 7 (Supp): S115.

Smithers BM, McLeod GR, Anderson J, Strutton G. The trials and tribulations of establishing selective lymphadenectomy for cutaneous melanoma. Melanoma Res. 1997; 7 (Supp): S120.

Smithers BM, Wu ZY, Parsons, PG, Roberts MS. The use of an animal model to explore conditions for isolated limb perfusion. Melanoma Res. 1997; 7 (Supp): S121.

Wu ZY, Smithers BM, Roberts MS. Melphalan dosing regimens for the management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res. 1997; 7 (Supp): S121.

Rhodes M, Gotley DG, Smithers BM, Menzies B, Branicki FJ, Nathanson LK. Laparoscopic Nissen fundoplication: lessons learned from 200 consecutive cases. Gut. 1995; 36 (Supp): A28.

Smithers BM, Hansen J, Schache D, Wall D. Prospective randomized trial of laparoscopic versus open appendicectomy for acute appendicitis. Surg Endosc 1994; 8:565.

Nicol DL, Smithers BM. Laparoscopic Nephrectomy for benign renal disease. Surg Endosc 1994; 8:557.

Smithers BM, Gotley DC. Thoracoscopic mobilization of the oesophagus in three stage oesophagectomy. Surg Endosc 1994; 8:490.

Grabs AJ, Smithers BM, Parsons P, Clark J, Roberts MS The influence of hypothermia on multiple melanoma cell lines treated with melphalan Aust NZ J Surg 1994; 64: 358-359.

Walpole ET, Beadle GF, McLeod GR. High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma. QMP 9105. Proc Am Soc Clin Oncol 1993

Wu ZY, Addison RS, Smithers BM, Roberts MS. The effects of perfusate conditions on the stability of melphalan in rat isolated limb perfusion. Clin Exp Pharmacol Physiol: (Supp) 1993;80.

Ross WB, Tweedy JH, Yeong YP, Wyman A, Smithers BM Intercostal blockade and pulmonary function after cholecystectomy. Current Surgery 1989; 46: 410.

BOOK CHAPTERSSmithers BM. Primary Melanomas of the Gastrointestinal Tract. In “Textbook of Melanoma” Ed Thompson J, Morton D, Kroon B. Pub: Martin Dunitz, London, England. 2004: 648-662.

Smithers BM, deWilt J. Isolated limb perfusion and infusion: preclinical studies and future directions. In “Textbook of Melanoma” Ed Thompson J, Morton D, Kroon B. Pub: Martin Dunitz, London, England 2004:438-442.

Burmeister BH, Poulsen M, Smithers BM, Kennedy D, Thompson D. Skin and Melanoma Cancer. Ch 16, UICC Manual of Clinical Oncology, 8th Edition, 2002

Burmeister BH, Poulsen M, Smithers BM, Kennedy D, Thompson D. Skin and Melanoma Cancer. Ch 16, UICC Manual of Clinical Oncology, 7th Edition, 1999

BOOK REVIEWSAcute Gastro-intestinal Bleeding. Diagnosis and Treatment. Aust NZ J Surg. 2005;75:474

OTHER PUBLICATIONSDebate – Gastroesophageal reflux disease: Zap, Sew or Wrap. Wrap: Laparoscopic fundoplication. Mark Smithers. Asia Pacific Digestive News. 2002;9:12.

Guidelines for the Management of Melanoma 1998 - Member of the Advisory Group who developed the document. This is now an NH&MRC guidelines book.

Clinical Practice Guidelines for the management of Melanoma 2008 – Member of the developmental working party. Chapter leader – “Appropriate Investigations”EDITORIAL BOARDSAsia Pacific Journal of Surgery 2008 - presentBritish Journal of Surgery 2008 - presentWorld Journal of Surgery 2009 - presentAustralian and New Zealand Journal of Surgery 2008 – present

JOURNAL REVIEWSAustralian and New Zealand Journal of SurgeryBritish Journal of SurgeryWorld Journal of SurgeryOncologyJournal of the American College of SurgeonsAnnals of Surgical OncologyFuture OncologyDiseases of the EsophagusEuropean Journal of Surgical Oncology

PRESENTATIONS AT CONFERENCES AND MEETINGS: 1997 - 2010# International Meeting

2011Invited PresentationsClinical trials in melanoma at the Princess Alexandra HospitalInternational Skin Cancer Research Workshop, Brisbane, March 2011

2010Invited PresentationsOutcomes from Minimally Invasive OesophagectomyThe role of salvage chemoradiation following recurrence of oesophageal cancerPreoperative chemotherapy or chemoradiation for gastric cancer.#The 3rd MATTU Oesophago-Gastric Cancer Symposium, Guildford, EnglandDiagnosis of Barrett’s Oesophagus and results of management of intramucosal adenocarcinoma of the oesophagus.Minimally invasive oesophageal resection for middle third cancers#3rd Asia Pacific Gastro-esophageal Cancer Congress, Kuala Lumpur, MalaysiaThe burden of follow up for melanoma.#4th Melanoma and Skin Cancer Centres Meeting, Sydney, AustraliaMinimising operative mortality following oesophagectomy#Australian and New Zealand Gastro-Oesophageal Surgeons Association Annual Scientific Meeting, Queenstown, New Zealand.Outcomes from Minimally Invasive Esophagectomy.New approaches to staging esophageal cancer#International Society for the Diseases of the Esophagus, Kagoshima, JapanThe emerging role of PET scanning in oesophageal cancer. The management of local and in-transit recurrence of cutaneous melanoma. Annual Scientific Congress, Royal Australiasian College of Surgeons, Perth, AustraliaOutcomes from Laparoscopic Hiatal Surgery.Cairns Gut Club, Cairns, AustraliaImproving outcomes from Oesophageal cancerTownsville Gut Club.

Reviewed presentations.Phase I evaluation of intralesional administration of oncolytic Picovirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma. DR Shafren, P Hersey, M SmithersChemoablation of metastatic melanoma with intralesional PV-10. S Agarwala, J Thompson, BM Smithers, MI Ross, BJ Coventry, DR Minor, CR Scoggins, EA Wachter.Expression of MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of screening tests for the DERMA trial. JJ Grob, M Santinami, U Trefzer, C Robert, B Smithers, L Mortier, E Levchenko, L Demidov, T jouary, F Grange, A Testori, J Thompson, O Peeters, B Dreno, JM Kirkman.4th Melanoma and Skin Cancer Centres Meeting, Sydney, AustraliaOesophageal cancer: Outcomes from surgery in Australia 2003-05. BM Smithers, T Corish, S Moore, P Fahey, D Whiteman.

Is radiation required in patients having preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomized phase II trial. BM Smithers, B Burnmeister, E Walpole, D Gotley, J Harvey, J Thomas.Minimally invasive oesophagectomy: health related-quality of life outcomes. J Hirst, M Smithers, D Gotley, I Martin, JThomas, A Barbour. Acute Appendicitis, does the laparoscopic operation lead to more complications. D Mackrill, Y Kan, A Stabler, M SmithersAnnual Scientific Congress, Royal Australiasian College of Surgeons, Perth, AustraliaDERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics. Trefzer V, Jovary T, Robert C, Santinami M, Levchenko E, Smithers B, Testori A, Peeters A, Kirkwood J, Dreno B. 6th Congress of the European Association of Dermo-Oncology, June 2010

2009Invited Presentations Clinical and Translational Research.

Developing an Academic Career in Surgery Workshop. Royal Australiasia College of Surgeons, Brisbane, Australia

Oesophageal Cancer – the role of surgery.Radiation Oncology Trainees Weekend, Gold Coast, Australia.

The role of radiation for resectable oesophageal cancer - A debate. The Australasian Gastro-intestinal Trials Group, Brisbane, Australia

Patient selection and outcomes for resection for HGD and intramucosal oesophageal cancer. The role of follow up after resection for oesophageal cancerAustralian Gastro-enterology Week, Sydney, Australia

Cutaneous melanoma: incidence, diagnosis, staging and latest treatment optionsConsumer Forum, Melanoma Patients Australia, Townsville, Australia.

2008Invited Presentations Video presentation of Revision fundoplicationSeminars in Operative Surgery, Adelaide, Australia The role of surgery for GIST North Coast Cancer Conference, Kingscliff, Australia Revision Fundoplication Minimally invasive oesophagectomy#International Society of Surgery conference, Townsville, Australia The outcomes form treating Achalasia Quality of life of anti-reflux surgery Minimally invasive surgery and mid oesophageal cancers Does surgical technique influence outcome in oesophageal cancer Oesophageal cancer: the last 20 years and 20 years into the future Minimally invasive oesophagectomy – A masterclass# Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. – Distinguished Invited Visitor The role of neoadjuvant therapy for oesophageal cancer.

5th Sino-Australian Surgical Oncology Meeting. Guangzhou, China The management of high grade dysplasia in Barrett’s oesophagusAustralian Gastroenterology Week, Brisbane, Australia The diagnosis and management of Barrett’s oesophagus High Grade Dysplasia in Barrett’s – EMR or Resection Video Presentation – Minimally invasive oesophagectomy# 2nd Asia Pacific Gastroesophageal Cancer Congress, Hong Kong. The management of high grade dysplasia in Barrett’s OesophagusSydney Upper GI Surgeons Society, Sydney Oesophageal Cancer: Patterns of Care in Australia. Smithers BM , Doecke J, Corish T, Moore

S, Whiteman D. The epidemiology of oesophageal cancer. Whiteman D, Smithers BM, Gotley DC, Pandeya

N, Sadeghi S, Green AC, Webb PM. Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney

Reviewed Presentations Quantitative positron emission tomography values predict prognosis in resectable

adenocarcinoma of the oesophagus. J Shenfine, A Barbour, D Wong, I Martin, J Thomas, DC Gotley, BM Smithers

11th World Congress of the International Society for Diseases of the Esophagus, Budapest, Hungary Minimally invasive esophagectomy for esophageal cancer: Analysis of patterns and prognostic

factors for recurrence. Thompson I, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A.45th Annual Scientific Meeting, Surgical Research Society of Australia and New Zealand A ranodomised phase II trial comparing pre-operative chemotherapy with pre-operative

chemoradiation therapy for localized carcinoma of the oesophagus. Burmeister BH, Smithers BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D, Barbour A, Gotley D.

Chemoablation of cutaneous and subcutaneous metastatic melanoma using PV-10. Thompson JF, Hersey P, Smithers BM, Coventry B, Ross MI, Wachter E.

Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney

Poster presentations Long-term patient reported outcomes of laparoscopic oesophageal myotomy with anterior

fundoplication in patients with achalasia. J. Shenfine, L. Koval, B. Menzies, B.M. Smithers, D.C. Gotley. (Winner of AUGIS Best Poster Presentation Prize).

Positron emission tomography standardised uptake values predict prognosis in resectable adenocarcinoma of the oesophagus J. Shenfine, A. Barbour, J. Thomas, D.C. Gotley, B.M.Smithers

Association of Upper Gastrointestinal Surgeons Annual Scientific Meeting, Liverpool, UK Jejunally fed patients post oesophagectomy / gastrectomy – are they getting all they need? –

An audit at the Princess Alexandra Hospital. Baumgartner L, Vivanti A, Smithers M. Minimally invasive esophagectomy for esophageal cancer: analysis of recurrence patterns and

prognostic factors of recurrence. Barbour A, Thompson I, Gotley DC, Jones M, Thomas J, Martin I, Smithers MB

Melanoma Patients Australia – A focus on patient support and advocacy. McFadyen, Herlaar H, Smithers M.

2007Invited Presentations The role of neoadjuvant therapy for adenocarcinoma of the esophagus The role of laparoscopic surgery for GIST tumours Video presentation of laparoscopic anti reflux surgery Laparoscopic repair of para-esophageal hernias Laparoscopic splenectomy – The gold standard? Trends in the management of Melanoma – the Queensland perspective.#Combined Annual Scientific meetings of South African Gastro-enterology Society / South African Society of Endoscopic Surgeons / Association of Surgons of South Africa, Sun City, South Africa Neoadjuvant therapy for oesophageal cancer – Are we there yet?Annual Scientific Congress, Royal Australasian College of Surgeons, Christchurch, New Zealand.Poster Presentations Surgery for early adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Hughes A, Smithers

BM, Thomas J, Martin I, Gotley DC, Barbour AP#60th Annual Cancer Symposium, Society of Surgical Oncology, Washington, USA

2006Invited Presentations Chemoradiation for Oesophageal Cancer Salvage Oesophagectomy after chemoradiation.# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia The present status of neoadjuvant therapy for oesphageal cancer. Annual Scientific Congress, Royal Australasian College of Surgeons, Sydney.Poster Presentations Is the quality of life improved by minimally invasive approaches to oesophagectomy?Smithers BM, Gotley DC, Thomas J, Doyle L. Outcomes from Salvage oesophagectomy post definitive chemoradiotherapy compared with preoperative

neoadjuvant chemoradiation.Cullinan M, Gotley DC, Thomas J, Martin I, Barbour A, Burmeister B, Harvey J, Thomson D, Walpole E, Smithers BM.# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of response and outcome. Barbour AP, Beller

E, Smithers BM.# 59th Annual Cancer Symposium, Society of Surgical Oncology, San Diego, USA Gene promoter methylation of ID4 and ARL4D in Barrett’s esophagus and esophageal adenocarcinoma. Smith E,

Nancarrow DJ, Pavey S, Hayward NK, De Young NJ, Kelly JJ, Whiteman DC, Smithers BM, Gotley DC, Drew PA.

#American Gastro-enterology WeekInternational Invitation Management of Cutanoeus Melanoma The management of Gastrointestinal stromal tumours Management of oesophageal cancerGeneral Surgery Training Day, Christchurch, New ZealandInvited Chairmanship Plenary Seminar: Hot topics in Gastro-Oesophageal Reflux Disease# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia The management of retroperitoneal sarcomas.Annual Scientific Congree, Royal Australasian College of Surgeons, Sydney.

2005Invited Presentations The present status of adjuvant therapy for melanoma The role of surgery for GIST tumours

Future directions and prevention in management of oesophageal cancerAnnual Scientific Meeting, Royal Australasian College of Surgeons, Perth, Australia.

Referreed Presentations A prospective phase II study of postoperative radiation therapy following nodal surgery for malignant melanoma

– trans Tasman radiation oncology group (TROG) study 96.06BH Burmeister, BM Smithers, EA Burmeister, KC Baumann, SR Davis, H Krawitz, C Johnson, N Spry.

Preoperative adjuvant chemoradiation therapy for oesophageal cancer – study 9401 and the aftermath.BH Burmeister, BM Smithers

32nd Annual Scientific Meeting of the Clinical Oncological Society of Australia, Brisbane, Australia. Trends for in-situ and invasive melanoma in Queensland, Australia, 1982 to 2002 Coory M, Baade P, Aitken J, Smithers BM, McLeod GR, Ring I.

#6th World Congress on Melanoma, Vancouver, CanadaPoster Presentation

Survival in Queensland from cutaneous invasive melanoma 1982-99 – A population study. Smithers BM, Coory M, Baade P, Aitken J, McLeod GR, Ring I.

#6th World Congress on Melanoma, Vancouver, Canada2004Invited Presentations

The role of chemoradiation for locally advanced oesophageal cancerAnnual Scientific Congress, Royal Australasian College of Surgeons, Melbourne

Practical management of Primary MelanomaSkin Cancer Workshop, General Practice Group, Gold Coast.

The present status of adjuvant therapy for oesophageal cancerIDSEA Meeting (International Diseases of the Esophagus, Australian Chapter), Sydney.2003Refereed Presentations

• A randomized phase III trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes.

BM Smithers, Burmeister BH, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph, J Millar, J North, E Walpole, D. Gotley.

56th Annual Cancer Symposium, Society of Surgical Oncology, Los Angeles, USA

• High rate of detection of primary aldosteronism, including surgically treatable forms, associated with the "non-selective" screening of hypertensives attending a recently established Hypertension Unit

Michael Stowasser, Richard D. Gordon, Thanuja G. Gunasekera, Diane C. Cowley, Gregory J. Ward, Colin Archibald and B. Mark Smithers Annual Meeting, US Endocrine Society.

Assessing the response of oesophageal carcinoma to neoadjuvant therapy using oesophagogastroscopy. Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E, Thomson D, Smithers BM.

A comparison of treatment outcome between adenocarcinoma and squamous cell carcinoma of the oesphagus. Lim KH, Thomas J, Brown WA, Harvey J, Burmeister B, Walpole E, Thomson D, Martin I, Gotley DC, Smithers BM. .

The role of surgery in the management of locally advanced oesophageal carcinoma. Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Smithers BM.

Royal Australasian College of Surgeons, Annual Scientific Congress, Brisbane, Aust.Invited Presentations

Laparoscopic Para-oesophageal Hernia Repair Management of high grade dysplasia in Barrett’s oesophagus Should we operate on locally advanced carcinoma of the oesophaus? The management of the high risk primary melanoma Adjuvant therapy for melanoma – a surgeon’s perspective.

Surgeons and clinical trials, are they compatible? Oesophagogastric cancer, the role of multi-disciplinary care and the effect of experience. Laparoscopic fundoplication for chronic cough.

John Goatcher Surgeon in Residence, Royal Perth Hospital, Perth, Aust. Neoadjuvant therapy for oesophageal cancer, results of recent trials.

Oncology meeting, Prince of Wales Hospital, Sydney, AustraliaInvited Chairmanship

• Esophageal Cancer: Chemoradiation? Surgery? Either? Both? Breakfast Session, 56th Annual Cancer Symposium, Society of Surgical Oncology, Los Angeles, USA

Multidisciplinary Tumour Board Case Discussions Management of gastric cancer

Royal Australasian College of Surgeons, Annual Scientific Congress, Brisbane, Aust 2002: Invited Presentations

• Debate: “The role of Laparoscopic Appendicectomy”• “Oesophageal Cancer – Trial proposals”• “Results of a prospective randomised trial of adjuvant therapy for operable oesophageal cancer.”

Annual Scientific Congress, Royal Australasian College of Surgeons, Adelaide• “Endoscopic oesophagectomy”

Seminars in Operative Surgery, Adelaide• The role of surgery for high grade dysplasia in Barrett’s oesophagus

Australian Gastroenterology Week, Gastroenterology Society of Australia, Adelaide• What should be the next trail for oesophageal cancer?• Surgical results following resection for high grade dysplasia in Barrett’s

Australasian Gastro-intestinal Trials Group, Annual Scientific Meeting, Hobart.• The management of oesophageal cancer

Caboolture Hospital Grand Rounds, Caboolture, Queensland.• Recent trends in oesophageal cancer

Cairns Gut Club, Cairns, Queensland• Update on neoadjuvant therapy for oesophageal cancer. The next trial?

International Society for Diseases of the Oesophagus, Australian Chapter, Lorne Victoria• The role of multidisciplinary care for oesophageal carcinoma.

Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney, Australia.

2001: Invited Presentations• “Update on the Surgery for Melanoma”

Gold Coast Oncology collaborative Group• “Oesophageal Cancer – The next collaborative trial”

Annual Scientific Congress, Clinical Oncological Society of Australia, Brisbane.• “Diagnosis and Management of Malignant Melanoma”

44th Annual Meeting RACGP (Qld Faculty), Gold Coast, Australia• “Oesophageal Cancer – Adjuvant Therapy”

Annual Scientific Congress, Royal Australasian College of Surgeons, Canberra, • “Management of Cutaneous Melanoma” Mater Hospital Collaborative Oncology Group, Brisbane

• “Management of Pancreatic Injury” Military and Civilian Trauma, Brisbane, Australia.

• “Management of Cutaneous Melanoma” Redcliffe Hospital Clinical Meeting

• “The present status of adjuvant therapy for Oesophageal Cancer” Australasian Gastrointestinal Trials Group, Annual Scientific Congress, Sunshine Coast, Queensland.

• “The role of a multidisciplinary clinic in the management of upper GI malignancy”• “Surgery for bulky groin secondaries of melanoma”• “A surgeons perspective of the role of adjuvant therapy for Melanoma”

Centenary Surgical Oncology Meeting, Brisbane, Australia

• “Long term results of Laparoscopic Fundoplication – The test of time” Asia Pacific Gastroenterology Congress, Sydney, Australia.2000: Refereed Presentations

• “Radiation Therapy – The forgotten tool in the fight against Melanoma” Burmeister B, Smithers BM

• “Where to now with adjuvant therapy in oesophageal cancer?” Smithers BM, Burmeister B Annual Scientific Meeting, Clinical Oncological Society of Australia, Adelaide, Australia

• “Phase II study assessing the role of radiotherapy after nodal surgery for metastatic melanoma.” Smithers BM, Burmeister B, Baumann K Annual Scientific Congress, Royal Australiasian College of Surgeons, Melbourne, Australia

• “Elective laparoscopic fundoplication for reflux: 1000 cases with 1-5 year follow-up” Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L, Menzies B, Nathanson L.

• “ Endoscopic versus open surgery for oesophageal cancer.” Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L. 7th World Congress of Endoscopic Surgery, 8th International Scientific Meeting of the Endoscopic and Laparoscopic Surgeons of Asia. SingaporeInvited Presentations

• “Adjuvant therapy for Malignant Melanoma” Head and Neck 2000 – Annual Meeting of the Australian and New Zealand Head And Neck Society, Gold Coast, Queensland.

• “The new surgical training”• “Endoscopic surgery and the oesophagus – techniques and results”• “Update on the management of Melanoma”

Keynote Speaker, Northern Australian Surgeon’s Club – Annual Scientific Meeting Port Douglas, Queensland

• “Barrett’s oesophagus natural history and surveillance.” Gotley DC, Smithers BM, Martin I, Sanders G, Doyle LM

• “Laparoscopic versus open surgery for oesophageal cancer.” Gotley DC, Smithers BM, Martin I, Bessell J, Doyle LM.

• “Oesophageal cancer: Neoadjuvant therapy.” Smithers BM, Gotley DC, Doyle LM. Annual Scientific Congress, Royal Australiasian College of Surgeons, Melbourne, Australia

• Panel Participation: Case Symposium- “Management of Oesophageal Cancer” GE Society of Queensland, 4th Annual Coolum Update in Gastroenterology and Hepatology, Sunshine Coast, Queensland, Australia.Posters # Comparison of quality of life after laparoscopic fundoplication: Do Barrett’s patients fare

worse DC Gotley, BM Smithers, LE Nathanson, I Martin, L Rutherford, L Doyle, B Menzies

# The natural history of high grade dysplasia in Barrett’s oesophagus. BM Smithers, DC Gotley, G Sanders, LM Doyle

# Outcomes after minimally invasive surgery for high grade dysplasia in Barrett’s oesophagus: short term follow up of Quality of life. LM Doyle, BM Smithers, DC Gotley, L Rutherford, C Swanson Organisation international d’Etudes Statistiques pour maladies de Oesophage (OESO) World 6th Congress, Paris, France

Invited as Chairman Session: Novel Therapies for Breast Cancer Annual Scientific Meeting, Clinical Oncological Society of Australia, Adelaide

1999: Refereed Presentations

• “Elective laparoscopic fundoplication for reflux: 1000 consecutive cases with 1-5 year follow-up” DC Gotley, BM Smithers, I Martin, J Bessell, L Doyle, B Menzies, L Nathanson

• “High Grade Dysplasia in Barrett’s Oesophagus” G Sanders, BM Smithers, DC Gotley, A Clouston Australian Gastroenterology Week, Brisbane, Australia

• “Dysphagia after laparoscopic fundoplication” JR Bessell, R Finch, DC Gotley, L Nathanson, BM Smithers, I Martin, L Doyle, B Menzies Annual Scientific Meeting, Surgical Research Society of Australasia, Cairns, Australia

• “Palliative Chemo-radiotherapy (CRT) in Advanced Oesophageal Cancer” J Harvey, B Burmeister, D Thomson, E Walpole, BM Smithers, D Gotley, J Bessell, L Doyle Annual Scientific Meeting, Clinical Oncological Society of Australia, Melbourne, Australia

Invited Presentations # “The Role of Chemoradiation in Oesophageal Cancer” Asian Surgical Association, Brisbane, Australia

• “Chemoradiation and surgery for Oesophageal Carcinoma” Guest Presentation, GI subcommittee, Victorian Clinical Oncology Group Melbourne, Australia

• “Intergroup Oesophageal Study of Preoperative Chemoradiation for Operable Oeophageal cancer”

Royal North Shore Hospital, Weekly Gastroenterology Meeting, Sydney, Australia• “Preoperative Chemoradiation for Operable Oesophageal Carcinoma”

Royal Melbourne Hospital, Melbourne, Australia # “Multicentre or Single Centre Clinical Trials?” Surgical Forum, International Clinical Trials Symposium, Sydney, Australia

• “The Management of Pancreatic Trauma” General Surgeons Australia, Scientific Meeting, Gold Coast, Australia

• “The Intergroup Oesophageal Cancer Trial” “Trends in the Management of Malignant Melanoma” Rural Surgeons Meeting, Victorian State Committee, Geelong, Victoria Posters

• “The role of chemo-radiotherapy prescribed by a multidisciplinary team for the palliative treatment of malignant dysphagia”. J Bessell, BM Smithers, DC Gotley, J Harvey, BH Burmeister, I Martin, E Walpole, D Thomson Australian Gastroenterology Week, Brisbane, AustraliaInvited as Chairman

• “Video Forum” Endoscopy Workshop, Australian Gastroenterology Week, Brisbane, Australia

• “Gastric Cancer Surgery in 1999” Annual Scientific Meeting, Clinical Oncological Society Of Australia, Melbourne, Australia

1998: INTERNATIONAL INVITATION• ATLS Courses x 2

Overseas Faculty Member, Queen Mary’s Hospital, Hong KongInvited Presentations

• "Gastro-oesophageal reflux disease” Rural Surgical Training Program – Trainees Meeting,Kingaroy, Queensland

# “Thoracoscopic Mobilisation of the Oesophagus” Millenium Surgical Meeting, Gold Coast, Queensland

• “The role of Chemoradiation in Oesophageal Cancer”• “Thoracoscopic Mobilisation of the Oesophagus”

Western Australian Clinical Oncology Group, Perth, West Australia• “Curative Therapy for Oesophageal Cancer- The role of surgery, chemotherapy and radiotherapy”• “Establishment of the Oesophageal Intergroup Trial”

Endoscopy and Research Workshops , Austrailian Gastroenterology Week Canberra, Australia

• “Current Concepts in Resusitation and Penetrating Trauma” Annual Scientific meeting, Australian and New Zealand Society of Anaesthetists, Queensland branch. Gold Coast, Queensland.

• “Current status of the Oesophageal Cancer Trial IG9401” Scientific Meeting, Australasian Gastro-Intestinal Trials Group, SydneyPosters

• “Microdialysis probe development and optimal conditions for melphalan determination in various tissues” T Dorizzi, ZY Wu, R Haslam, BM Smithers, J. Thompson, C Anderson, MS Roberts

• “Melphalan tissue concentration in isolated limb perfusion by using the technique of microdialysis” ZY Wu, R Haslam, T Dorizzi, BM Smithers, J Thompson, C Anderson, MS Roberts Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, Sydney, Australia

• “Previous radiation for breast cancer – an unusual cause of carcinoma of the oesophagus. B Matheson, BH Burmeister, BM Smithers, D Gotley, JA Harvey, L Doyle.

• “Retrospective analysis of concurrent radiation and 5-Flurouracil (5FU) alone for oesophageal cancer”. HG Juffs, DB Thomson, ET Walpole, JF MacKintosh, BH Burmeister, JA Harvey, BM Smithers, DC Gotley Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney, Australia Invited as Chairman

• “Management of Gastro-oesophageal junction cancer” Annual Scientific Meeting of The Clinical Oncological Society of Australia Sydney, Australia1997: Refereed Presentations

• “Thoracoscopic oesophageal mobilization for carcinoma”. BM Smithers, DC Gotley, C Smith.

• “Successful application of laparoscopy to correction of gastro-oesophageal reflux”. DC Gotley, BM Smithers, B Menzies, L Nathanson.

• “Establishing selective lyphadenectomy for cutaneous melanoma”. BM Smithers, GRC McLeod, J Anderson, G Strutton. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane

• “Radiation Therapy following nodal dissection for malignant melanoma: a report on a phase II study”. BH Burmeister, MG Poulsen, BM Smithers, GR McLeod, JA Harvey, K Morton. 4thWorld Conference on Melanoma, Sydney, AustraliaInvited Presentations

• "What operation should be performed for carcinoma of the gastro-oesophageal junction" Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, Australia.• "What not to do in management of malignant melanoma"

4th World Conference on Melanoma, Sydney, Australia.• "Future directions of General Surgery in Queensland"

Royal Australasian College of Surgery, Queensland Division Annual Scientific Meeting, Yeppoon, Queensland, Australia

• "Oesophageal Cancer" – Breakfast session. Australian Gastroenterology Week, Brisbane, Australia • "Thoracoscopic Oesophageal Mobilization" – Video presentation.• "Diagnosis and Treatment of Early Upper Gastrointestinal Cancer – Australian View "

III Annual Gold Coast Surgical Weekend Conference• "Current Management of Oesophageal Cancer"

Surgical Meeting, Liverpool Hospital, Sydney, AustraliaPosters

• "Metastatic malignant melanoma to the orbit: a report of nine cases". JA Harvey, BH Burmeister, BM Smithers, GRC McLeod.

• "The trials and tribulations of establishing selective lymphadenectomy for cutaneous melanoma". BM Smithers, GRC McLeod, J Anderson, G Strutton

• "The use of an animal model to explore conditions for isolated limb perfusion". BM Smithers, ZY WU, PG Parsons, MS Roberts.

• "Melphalan dosing-regimens for the management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hind limb".

ZY Wu, BM Smithers, MS Roberts. 4th World Conference on Melanoma, Sydney, AustraliaInvited as Chairman

• "Management of Local Recurrence of Malignant Melanoma". Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, Australia.

Jan 2011